Prognostic impact of high-intensity lipid-lowering therapy under-prescription after acute myocardial infarction in women

Orianne Weizman,Marie Hauguel-Moreau,Victoria Tea,Franck Albert,Paul Barragan,Jean-Louis Georges,Nicolas Delarche,Mathieu Kerneis,Vincent Bataille,Elodie Drouet,Etienne Puymirat,Jean Ferrières,François Schiele,Tabassome Simon,Nicolas Danchin,,F Albert,E Aliot,J Allal,S Allam,G Allard-Latour,G Amat,M Amor,M Andriambololona,P Assayag,P Asseman,J-L Banos,G Baradat,J Bardet,P Bareiss,C Barnay,J-P Bassand,M Baudouy,P Baudouy,G Baulleret,P Bazin,P Beaufils,Y-M Beauverger,J Becquart,L Belle,J Berland,P Bernard,E Beruben,G Bessede,P Bickert,A Bineau-Jorisse,J-J Blanc,D Blanchard,A Bonneau,P Bonnet,J-L Bourdon,C Boureux,P Boutaud,J-M Bouvier,H-P Brunel,P Cazenave,R Cador,P Cardinaud,B Carette,Carlioz,F Casteigt,S Cattan,P Cazaux,C Chaussard,B Charbonnier,J Chounet,O Claudon,G Coatantiec,A Coeurderoy,G Convert,P Coste,P Coulon,J Coupillaud,G Courdier,J-P Cressens,A Cribier,J D'Amato,P Dambrine,N Danchin,X De Boisgelin,N Delarche,G Dentan,S Destrac,R Deturck,J Dewilde,A Dibie,P Djiane,J-P Doazan,P Druelles,O Dubourg,F Duclos,J-J Dujardin,M-N Dulhoste,P Dupouy,J Elaerts,Elgohary,S Elhadad,M Escande-Orthlieb,H Escojido,B Estampes,P Eymerit,P Fichter,D Flammang,M Font,M Fourdilis,P Fournier,M Francoual,P Fromage,D Galley,H Garnier,O Gauffre,L Genet,P Geslin,M Ghanem,S Godard,J-P Godenir,C Goburdhun,D Grison,G Grollier,C Gueniche,O Guenot,P Gueret,Y Guerin,J-P Guillot,C Gully,J-J Halary,G Hannebicque,C Mycinski,M Hanssen,D Heiligenstein,A Heraudeau,P Hochart,A Hueber,R-G Huguet,B Huret,H Jambert,Jebai,J Jullien,B Karsenty,K Khalife,J-C Kahn,G Kirkorian,P Lagorce,Lahneche,B Lancelin,M Lang,P Lanteme,G Lapeyre,H Lardoux,A Lassabe,Y Laurent,F Leclercq,L Ledain,T Lefevre,C Lemoine,L Levai,Le Marrec,P Mabo,J Machecourt,D Magnin,J-P Mailler,J-J Marier,F Marco,J-L Marcon,M Martelet,P Meimoun,P Messner-Pellenc,B Mettauer,J-P Metzger,T Meurice,J-P Monassier,A Monnier,J Monsegu,J-M Montely,J Morice,J-M Mossard,Normand,Olive,I Oltean,J-M Paemelaere,F Paganelli,J-Y Pagny,M Pailloncy,M-C Palcoux,J-L Parola,B Peltier,J-M Pernes,M Pichene,E Pierre-Justin,G Pochmalicki,O Poitrineau,J Ponsonnaille,J-E Poulard,P Pruvost,J Puel,P Quandalle,J-C Quiret,G Rebuffat,R Rihani,B Ritz,P Rioux,J Rouffaud,D Rondepierre,J-F Ronteix,E-H Saadouni,R Sader,P Sans,L Sarfati,B Sivery,M Slama,F-X Soto,X Tabone,F Thieuleux,J-Y Thisse,G Thourot,M Tissot,T-A Tissot,C Toussaint,G Traisnel,Tran,G Tremeau,A Vahanian,P-L Michel,B Valeix,B Vahdat,H Vergnouix,M Viallet,D Vilarem,P Virot,J Vittrant,S Weber,J-E Wolf,P Wyart,A Zabel,M Zupan Sihcus,Y Cottin,P Coste,T Lognogne,G Roul,B De Breyne,F Moulin,K Khalife,G Vanzetto,D Carrie,B Jouve,G Leurent,F Schiele,L Hammer,E Faure,V Probst,J Boschat,P Motreff,B Ritz,C Le RAY,S Andrieu,V Lucke,G Rouault,J P Faure,G Levy,F Leclercq,C Robin,Y Valy,P Asseman,N Danchin,L Schmutz,N Delarche,J Y Wiedemann,X Tabone,G Pacouret,J Schwob,P Lim,L Orion,M El Moujahid,P Druelles,L Belle,J Fajadet,J M Perron,P Henry,P Rosak,G Ducrocq,C Tron,N Duvilla,S Elhadad,T Demicheli,V Rouselle,S Cazaux,J Ballout,L Genet,B Herce,J L Banos,G Jarry,H Benamer,J M Montely,P Joly,F Paganelli,R Delaunay,T Tibi,G Dentan,P Boulard,D Champagnac,F X Soto,J L Bonnet,Y Le Francois,F Duclos,A Luycx-Bore,C Boureux,J P Collet,P Dupouy,R Ravan,M Amor,P Bonnet,X Marchand,R Bourkaib,H Ben AMER,B Maillier,R Pilliere,P Bernard,D Coisne,R Berthier,M Fayard,B Magdelaine,M Pichene,S Werquin,H Aelion,A Boccara,J Armengaud,P Meyer,E Ferrari,P Jarnier,B Karsenty,J C Bodart,T Jullien,P Barragan,B Koujan,E Dadez,B Huret,Z Boueri,P Graux,P Lantelme,H Le BRIS,L Nait Saidi,F Raoux,M Coco,J P Monassier,X Favereau,C Brasselet,G Traisnel,P Dupouy,O Nallet,A Cerisier,B Chevalier,A Furber,A Koegler,S Sedighian,P Y Petiteau,S Perrot,G Bessede,A Verdun,J L Fourrier,L Maillard,P Brunel,J Coupillaud,M Slama,R Sader,J Darchis,J P Elkaim,B Vahdat,H Kamal,M Zaehringer,F Philippe,R Cador,A Bettioui,J E Poulard,G Allard Latour,D Broucqsault,J Ettori,F Bernasconi,F Casteigt,A Hueber,B Mettauer,P Schiano,P Loiselet,J L Roynard,M Martelet,J P Godenir,J J Dujardin,H Saadouni,P Fromage,L Michel,N Ley,C Breut,X Faverau,E Fonseca,S Allam,E Beruben,P Admant,A Cohen,I Laurent,J Haas,P Eymerit,M Lescure,A Gabriel,A Belhassane,J Litalien,J Souk-Aloun,J L Fourrier,P Rioux,F Brunelle,D Hamani,L Sarfati,F Thieuleux,A Berenfeld,P Airaud,E Decoulx,V Heroguelle,J P Claudel,A Ribier,G Cellarier,D Magnin,R Megbemado,U Mischke,D Baborier,J Y Thisse,B Jellouli,J M Demarcq,J P Hugon,F Funck,M Mteirek,J L Bourdon,L Dutoit,A Bineau-Jorisse,P Joly,J P Ray,F Tarragano,H Jebai,G Baradat,M Tissot,G Bureau,V Decourcelle,J J Halary,M P Bienvenu,B D'Hautefeuille,G Gosselin,E Coz,O Claudon,D Galley,R Benderbous,S Destrac,B Jouve,P Peycher,P Rumeau,L Leborgne,A Furber,V Lucke Simandoux,F Bernasconi,F Duclos,F Saint-Pierre,J Grebet,V Haddad,P Jessen,F Walylo,L Dutoit,F Soto,S Andrieu,J Sainsous,A Faure,J Labeque,K Dumessi,Y Lefrancois,L Baciulescu,P Petiteau,F Schiele,C Mycinski,A Kadri,N Marque,A Gommeaux,O Darremont,M Laine,N Mansencal,O Nugue,N Mayaud,X Tabone,P Castellant,J Faure,B De Breyne,F Beygui,P Richard,G Tremeau,T Tibi,R Grossetete,P Salva,E Beruben,M Fayard,V Descotes-Genon,D Angoulvant,F Houeze,O Poitrineau,P Pon-Gabrielsen,M Slama,P Motreff,S Greciano,P Plastaras,A Luycx Bore,R Berthier,C Baixas,P Aouate,P Lim,J Roynard,A Farhat,Y Cottin,G Napporn,O Jabourek,S Werquin,B Baala,P Admant,C Breton,S Taamallah,G Dentan,X Lamit,A Hidoud,N Poulos,S Marchand,F De Poli,A Diallo,L Orion,Y Valy,G Vanzetto,B Beaudet,Y Deslandes,C Charbonnel,T Demichelli,P Lesault,P Assayag,P Rosak,S Gostine,O De Tauriac,M El Moujahid,P Chevalevreau,G Lemesle,T Meurice,T Bontemps,V Aboyans,J Landel,F Durup,P Cazaux,T Perret,B Harbaoui,P Bert-Marcaz,J Bouvier,F Paganelli,J L Bonnet,P Khanoyan,F Bouriche,T Lefevre,B Jellouli,M Gasmi,K Khalife,F Moulin,P Rougier,E Somody,A De Labriole,C Milon,O Nallet,P Bonnet,R Roche,G Levy,F Leclercq,A Boccara,P Cornec,D Bresson,R Schultz,M Pichene,F Digne,V Probst,J C Dib,J Ballout,E Ferrari,E Maupas,G Cayla,G Lucas,O Genee,O Dibon,J Saal,P Henry,A Cohen,J Silvain,R Cador,O Varenne,N Danchin,G Ducrocq,N Delarche,P Jarnier,P Sultan,B Karsenty,P Coste,X Marchand,D Coisne,F Funck,L Belle,T Joseph,S Chayeb,C Brasselet,B Herve,P Druelles,P Mabo,L Flork,A Kaaki,J Souk Aloun,G Legros,N Du Villa,C Tron,G Taldir,P Guyon,K Isaaz,Z Haddad,H Jebai,A Mihoubi,M Brignon,R Temam,D Saouli,C Godreuil,A Chmait,J Remy,D Tchtchoua,P Henon,M Deltreuil,A Grentzinger,C Richard,D Pacaud,J Ettori,S Ledon,M Zaehringer,P Ohlmann,A Scemama,T Beard,J Dupont,R Poyet,B Farah,M Elbaz,E Delcoux,A Muligo,B Maillier,A Berenfeld,S Champin,K Moussa,B Popovic,C Le Ray,S Onceanu,X Marcaggi,D Maes,E Salengro

DOI: https://doi.org/10.1093/eurjpc/zwae255

IF: 8.526

2024-08-05

European Journal of Preventive Cardiology

Abstract:Abstract Aims Women are less likely to receive lipid-lowering therapy (LLT) after acute myocardial infarction (AMI). We analysed whether this under-prescription currently persists and has an impact on long-term outcomes. Methods and results The FAST-MI programme consists of nationwide registries including all patients admitted for AMI ≤ 48 h from onset over a 1 month period in 2005, 2010, and 2015, with long-term follow-up. This analysis focused on high-intensity LLT (atorvastatin ≥ 40 mg or equivalent, or any combination of statin and ezetimibe) in women and men. Women accounted for 28% (N = 3547) of the 12 659 patients. At discharge, high-intensity LLT was significantly less prescribed in women [54 vs. 68% in men, P < 0.001, adjusted odds ratio (OR) 0.78(95% confidence interval (CI) 0.71–0.87)], a trend that did not improve over time: 2005, 25 vs. 35% (P = 0.14); 2010, 66 vs. 79% (P < 0.001); 2015, 67 vs. 79.5% (P = 0.001). In contrast, female sex was not associated with a lack of other recommended treatments at discharge: beta-blockers [adjusted OR 0.98(95% CI 0.88–1.10), P = 0.78], or renin–angiotensin blockers [adjusted OR 0.94(95% CI 0.85–1.03), P = 0.18]. High-intensity LLT at discharge was significantly associated with improved 5 year survival and infarct- and stroke-free survival in women [adjusted hazard ratios (HR) 0.74(95% CI 0.64–0.86), P < 0.001 and adjusted HR: 0.81(95% CI: 0.74–0.89); P < 0.001, respectively]. Similar results were found using a propensity score-matched analysis [HR for 5 year survival in women with high-intensity LLT: 0.82(95% CI 0.70–0.98), P = 0.03]. Conclusion Women suffer from a bias regarding the prescription of high-intensity LLT after AMI, which did not attenuate between 2005 and 2015, with potential consequences on both survival and risk of cardiovascular events.

cardiac & cardiovascular systems